A phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma

Cancer

Volumn 91, Issue 11, 2001, Pages 2039-2045

  Ferrari, Anna C ^a,d   Chachoua, Abraham ^b   Singh, Harvinder ^a   Rosenthal, Mark ^c   Taneja, Samir ^b   Bednar, Myron ^a   Mandeli, John ^a   Muggia, Franco ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Hormone refractory prostate carcinoma; Intermittent estramustine; Response; Toxicity; Weekly paclitaxel

Indexed keywords

ESTRAMUSTINE; GONADORELIN AGONIST; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW TOXICITY; BONE SCINTISCANNING; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; EDEMA; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HUMAN; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRAMUSTINE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0035370365     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010601)91:11<2039::AID-CNCR1230>3.0.CO;2-R     Document Type: Article

References (31)

1. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71(3 Suppl):1098-109.
2. Tannock IF, Osoba D, Stockier MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormoneresistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-64.
3. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999;17(8):2506-13.
4. Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 1994;12(10):2005-12.
5. Ellerhorst JA, Tu SM, Amato RJ, Finn L, Millikan RE, Pagliero LC, et al. Phase II trial of alternating weekly chemotherapy for patients with androgen-independent prostate cancer. J Clin Oncol 1997;3:2371-6.
6. Hudes G, Chapman A, McAleer C, Greenberg R. Taxol and estramustine in hormone-refractory prostate cancer. Cancer Invest 1994;13:47-8.
7. Petrylak DP, Macarthur RB, O'Connor J, Shelton G, Judge T, Balog J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 1999; 17(3):958-67.
8. Crossin KL, Carney DH. Microtubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and by epidermal growth factor. Cell 1981;27:341-50.
9. Stearns ME, Tew KD. Antimicrotubule effects of estramustine, an antiprostatic tumor drug. Cancer Res 1985;45:3891-7.
10. Horwitz SB. Mechanisms of action of taxol. Trends Pharmacol Sci 1992;13:134-6.
11. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996;56:1253-5.
12. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999;17(3):1061-70.
13. Wang LG, Liu XM, Kreis W, Budman DR. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 1999;44: 355-61.
14. Speicher LA, Barone L, Tew KD. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res 1992;52:4433-40.
15. Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997;15(9):3156-63.
16. Torres K, Horwitz SB. Mechanism of Taxol-induced cell death are concentration dependent. Cancer Res 1998;58: 3620-6.
17. Hainsworth JD, Greco FA. Paclitaxel administered by 1-hour infusion. Preliminary results of a Phase I/II trial comparing two schedules. Cancer 1994;74(4):1377-82.
18. Chang AM, Boros L, Asbury R, Hiu L, Rubins J. Dose escalation study of 1-hour weekly paclitaxel administration in patients with hormone refractory prostate cancer. Semin Oncol 1997;5(Suppl 17):69-71.
19. Rosenberg SK, Muggia F, Russell C, Parimoo D, Israel D, Rogers M, et al. Estramustine phosphate (EMP) and 3H-paclitaxel: a Phase I study in women with refractory cancer. Proc Am Soc Clin Oncol 1996;15:181.
20. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993;11:607-15.
21. Smith D, Dunn RL, Strawderman MS, Pienta KJ. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 1998;16(5):1835-43.
22. Scher H, Kelly WMK, Zhang Z-F, Ouyang P, Sun M, Schwartz M, et al. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst 1999;91(3):244-51.
23. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate specific antigen working group. J Clin Oncol 1999;17:3461-7.
24. Norton L. Implications of kinetic heterogeneity in clinical oncology. Semin Oncol 1985;12:231-35.
25. Fennelly D, Aghajanian C, Shapiro F, O'Flaherty C, McKenzie M, O'Connor C, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997;15(1):187-92.
26. Hainsworth JD, Urba WJ, Hon JK, Thompson KA, Stagg MP, Hopkins LG, et al. One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter, Phase II trial. Eur J Cancer 1998;34(5): 654-8.
27. Reference PD. Emcyt. physicians desk reference, volume 52. 1998:2267-8.
28. Hudes G. Estramustine-based chemotherapy. Semin Urol Oncol 1997;15(1):13-9.
29. Roth BI, Yeap BY, Wilding G, Kasimis B, McLeod D, Loehrer PJ. Taxol in advanced, hormone-refractory carcinoma of the prostate. A Phase II trial of the Eastern Cooperative Oncology Group. Cancer 1993;72(8):2457-60.
30. Trivedi C, Redman B, Flaherty LE, Kucuk O, Du W, Heilbrun LK, et al. Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer 2000;89(2):431-6.
31. Yagoda A, Smith JA Jr., Soloway MS, Tomera K, Seidmon EJ, Olsson C, et al. Phase II study of estramustine phosphate in advanced hormone-refractory prostate cancer with increasing prostate specific antigen levels [abstract 686]. J Urol 1991;145:384A.